Category: 170161-27-0

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: An excess of anhydrous K2CO3 was added to a solution of di- or triprotected cyclam (1 mmol) in dry CH3CN (50 mL) and then a solution of 2,2′-bis(bromomethyl) biphenyl (1 or 2 mmol) in the same solvent was added. The suspension was kept at reflux with strong stirring for 3-4 days. The resulting mixture was filtered and the solvent was vacuum distilled to give a residue that was purified by column chromatography over silica with CH2Cl2/MeOH as the eluent., 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Burguete, M. Isabel; Clares, M. Paz; Garcia-Espana, Enrique; Luis, Santiago V.; Querol, Manel; Marti-Centelles, Vicente; Tetrahedron; vol. 67; 25; (2011); p. 4655 – 4663;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

To a solution of tri-Boc cyclam S7 (3.80 g, 7.59 mmol) in anhydrous CH3CN (160 mL) were added Na2CO3 (0.956 g, 9.10 mmol) and ethyl bromoacetate (1.00 mL, 9.02 mmol). The reaction mixture was stirred at reflux under Ar overnight. The insoluble salts were filtered, and the filtrate was concentrated under reduced pressure. The residuewas purified by flash column chromatography (silica gel, EtOAc:hexane = 1:2 rampingto 1:1) to give S9 as a white foam (4.06 g, 91%). RF (EtOAc:hexane = 1:1) 0.67. IRvmax/cm 2974, 2933, 2869, 1737, 1685, 1465, 1411, 1366, 1292, 1240, 1154, 1032,772, 731. 1H NMR (300 MHz, CDCI3) 5 1.26 (t, 3H, J 7.2, COOCH2CH3), 1 .46 (5, 27H, 3 C(CH3)3), 1.60-1.78 (m, 2H, CH2CH2CH2), 1.85-2.00 (m, 2H, CH2CH2CH2), 2.60-2.72(m, 2H, CH2N(CH2COOCH2CH3)CH2), 2.80-2.90 (m, 2H, CH2N(CH2COOCH2CH3)CH2),3.22-3.65 (m, 14H, 3 x CH2N(Boc)CH2 & NCH2COOCH2CH3), 4.14 (q, 2H, J 7.2, COOCH2CH3). ?3C NMR (75 MHz, CDCI3) 5 14.2, 27.0, 28.4, 45.2, 46.8, 47.1, 47.3,48.3, 51.8, 52.9, 53.6, 55.3, 60.1, 79.4, 155.4, 155.6, 170.9 (twelve carbon signals overlapping or obscured). MS (ESI) m/z 587.0 ([M+H], 6%), 609.1 ([M+Na], 100%), 1194.9 ([2M+Na], 47%). The spectroscopic data were in agreement with those in the literature.27?28, 170161-27-0

The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; THE UNIVERSITY OF SYDNEY; RUTLEDGE, Peter; TODD, Matthew; TRICCAS, James Anthony; WO2014/153624; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The y-carbaldehyde intermediates (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (35.7 mg, 71.0 mumol) in MeOH (1.0 mL) and AcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (8.90 mg, 142 mumol) was added slowly to the reaction mixture and stirred at room temperature for 24 h. The reaction mixture was poured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was then washed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain the corresponding tri-N-Boc-protected amine intermediates (68.9 mg), which were used in the next step without purification. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 6-12.

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

(e) Synthesis of BRI7160 and BRI7161; The compounds were prepared according to Reaction Scheme 4: Compound 4 was prepared following the method of R. Guilard et al., Bull. Soc. Chim. Fr., 1996, 133, 65-73.A magnetically stirred suspension of compound 4 (430 mg, 0.86 mmol), (4-bromomethyl) methyl benzoate (217 mg, 0.95 mmol), KHCO3 (172 mg) and K2CO3 (174 mg) in dry acetonitrile (17 ml) was heated at reflux for 18 h under an atmosphere of nitrogen. The reaction mixture was cooled to room temperature then concentrated under reduced pressure to yield a straw coloured oil which was purified by flash chromatography (silica, 5% methanol/dichloromethane elution). Concentration of the appropriate fractions (RF 0.38) afforded adduct 5a as a clear, colourless oil. Mass Spectrum (APCI) m/z 649 [(M+H)+, 100%]., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Patent; Prana Biotechnology Ltd; US7704987; (2010); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A suspension of compound 21 (1.59 g), commercially available (Aldrich Chemical Co., Milwaukee, WI) compound 22 (0.8 g) and K2CO3 (0.48 g) in DMF (15 ml) is stirred at 600C overnight. The reaction mixture is concentrated to a thick oil and filtered through a glass syringe filter, dissolved inCH2Cl2 and purified by column chromatography (silica) to give compound 23 (1.96 g)

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLYCOMIMETICS, INC.; MAGNANI, John, L.; SARKAR, Arun, K.; WO2010/126888; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of tri-Boc cyclam S7 (437 mg, 0.873 mmol) in anhydrous CH3CN (26 mL)were added Na2CO3 (370 mg, 3.49 mmol) and propargyl bromide (-80% in toluene, 156pL, 1 .05 mmol). The reaction mixture was heated at reflux under N2 overnight. Theinsoluble salts were filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, EtOAc:hexane =7:3) to give S11 as a white foam (446 mg, 95%). RF (EtOAc:hexane = 7:3) 0.58. m.p.47-48 C (lit.45?66 m.p. 4749 C). IR Vmax/cm1 3305, 3243, 2976, 2932, 2871, 2826,1681, 1463, 1410, 1365, 1240, 1150. 1H NMR (200 MHz, CDCI3) 5 1.40 (5, 27H, 3 xC(CH), 1.55-1.75 (m, 2H, CH2CH2CH2), 1.75-1.95 (m, 2H, CH2CH2CH2), 2.12 (5, 1H,CCH), 2.46 (t, 2H, J 5.4, CH2N(CH2CCH)CH2), 2.55-2.70 (m, 2H, CH2N(CH2CCH)CH2), 3.10-3.50 (br m, 14H, 3 x CH2N(Boc)CH2 & NCH2CCH). MS (ESI) m/z539.4 ([M+H], 100%), 561.5 ([M+Na], 28%). The spectroscopic data were inagreement with those in the literature.25?26, 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; THE UNIVERSITY OF SYDNEY; RUTLEDGE, Peter; TODD, Matthew; TRICCAS, James Anthony; WO2014/153624; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A solution of 2,6-bis(bromomethyl)quinolineS7 (63.7 mg, 200 mumol) was added to solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (101 mg, 200 mumol), bis(pyridin-2-ylmethyl)amine (40.3 mg, 200 mumol) and K2CO3 (55.9 mg, 200 mumol) in CH3CN (2.50 mL) under N2 and stirred at 80 C for 48 h under microwave irradiation. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with Na2SO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediates. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds with the mixture of regioisomers 23AB., 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

A mixture of terephthalaldehyde (134 mg, 1.0 mmol) and triBoc-cyclam (250 mg, 500 mol) inDCM (10 mL) was stirred at ambient temperature for 2 h and then sodium triacetoxyborohydride (318mg, 1.5 mmol) was added. The mixture was stirred overnight at ambient temperature. The reaction wasquenched with aqueous NaHCO3, the layers were separated and the aqueous layer was extracted withdichloromethane. The combined organic layers were dried over anhydrous sodium sulfate andevaporated. The crude residue was purified by Combi-Flash (silica gel; ethyl acetate in hexanes) to givePKS8204 (198 mg, 64%) as a colorless gum, which turned into a fluffy solid under vacuum., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Article; Amor-Coarasa, Alejandro; Kelly, James M.; Singh, Pradeep K.; Ponnala, Shashikanth; Nikolopoulou, Anastasia; Williams, Clarence; Vedvyas, Yogindra; Jin, Moonsoo M.; David Warren; Babich, John W.; Molecules; vol. 24; 8; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

500 mg of compound 17-3 and 1.3 g of compound 17-1 were dissolved in 20 mL of acetonitrile, 680 mg of potassium carbonate was added, and the mixture was heated to reflux overnight, cooled to room temperature, filtered, and concentrated. Mix sample was dissolved in dichloromethane, separated by column chromatography (PE: EA = 20: 1-1: 1) to give a colorless waxy compound 17-4 500mg, Yield: 39.6%., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Patent; Shenzhen Xiaxiwan Pharmaceutical Technology Co., Ltd.; Qi Fei; Xia Junxia; Zhang Zaijun; Wang Liang; (27 pag.)CN109988153; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: The y-carbaldehyde intermediates (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (35.7 mg, 71.0 mumol) in MeOH (1.0 mL) and AcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (8.90 mg, 142 mumol) was added slowly to the reaction mixture and stirred at room temperature for 24 h. The reaction mixture was poured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was then washed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain the corresponding tri-N-Boc-protected amine intermediates (68.9 mg), which were used in the next step without purification. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 6-12.

170161-27-0, 170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI